A decent partnership that grants us $50 million up
Post# of 72440
1) Provide a clear path to phase 3 with funded trials.
2) Eliminate all balance sheet issues and provide funding to continue other development.
3) Provide third-party validation of the assets and some concrete valuation floor.
The reason they have been able to push this so far down is the lack of clear funding for the path forward. You will not need drug sales revenues to increase the stock price substantially from here.
We may suffer short attacks again in the future but they lack teeth when we don't rely on our stock price for financing. That is why I hope the upfront on the first deal is enough to carry us to even larger milestone payments. They may temporarily bring us down 30% but the price always recovers. They have been so successful here because in conjunction with their attacks and manipulation, the company has been selling 10s of millions of shares to Aspire each year.